HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 58812

HXB2 Location  Gag(147-155)   Gag Epitope Map
View variants at this location
Epitope ISPRTLNAW   Epitope Alignment
Variants
{s}lSPRTLNAW   observed variant
{p}lSPRTLNAW   observed variant
lSPRTLNAW   observed variant
{p}ISPRTLNAW   observed variant
{p}IaPRTLNAW   observed variant
{p}ItPRTLNAW   observed variant
{p}ltPRTLNAW   observed variant
ItPRTLNAW   observed variant
IlPRTLNAW   observed variant
Epitope Name ISW9
Species (MHC/HLA human(B*57:01)

Variant Details

Showing all: 9 variant(s).


Variant ID.  3172
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {s}lSPRTLNAW
Mutations A/S I/L
Epitope Location A-1S I1L
HXB2 Location A145S I146L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {s}lSPRTLNAW{V}, were seen for ISW9 by 13 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701.


Variant ID.  3173
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}lSPRTLNAW
Mutations A/P I/L
Epitope Location A-1P I1L
HXB2 Location A145P I146L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {p}lSPRTLNAW{V}, were seen for ISW9 by 104 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701 and at 179 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701.


Variant ID.  3174
Epitope Seq.  ISPRTLNAW
Variant Seq.  lSPRTLNAW
Mutations I/L
Epitope Location I1L
HXB2 Location I146L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, A|lSPRTLNAW|V, was seen for ISW9 by 271 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701; at 45 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701; from 144 weeks post-infection in patient 5 (P5) who carried alleles A*0101,A*0101,B*0801,B*5701 and from 17 weeks post-infection in patient 6 (P6) who carried alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3175
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}ISPRTLNAW
Mutations A/P
Epitope Location A-1P
HXB2 Location A145P
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking mutation, {p}ISPRTLNAW{V}, was seen for ISW9 from 75 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701; from 60 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701; and from 10 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.


Variant ID.  3176
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}IaPRTLNAW
Mutations A/P S/A
Epitope Location A-1P S2A
HXB2 Location A145P S147A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {p}IaPRTLNAW{V}, were seen for ISW9 by 274 weeks post-infection in P3 who carried HLA alleles A*2402 , A*3201, B*4002, B*5701.


Variant ID.  3177
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}ItPRTLNAW
Mutations A/P S/T
Epitope Location A-1P S2T
HXB2 Location A145P S147T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, {p}ItPRTLNAW{V}, were seen for ISW9 by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.


Variant ID.  3178
Epitope Seq.  {A}ISPRTLNAW
Variant Seq.  {p}ltPRTLNAW
Mutations A/P I/L S/T
Epitope Location A-1P I1L S2T
HXB2 Location A145P I146L S147T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope mutation, {A}ItPRTLNAW{V}, was seen for ISW9 by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.


Variant ID.  3179
Epitope Seq.  ISPRTLNAW
Variant Seq.  ItPRTLNAW
Mutations S/T
Epitope Location S2T
HXB2 Location S147T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations, A|ItPRTLNAW|V, were seen for ISW9 by 316 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.


Variant ID.  3180
Epitope Seq.  ISPRTLNAW
Variant Seq.  IlPRTLNAW
Mutations S/L
Epitope Location S2L
HXB2 Location S147L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Flanking and epitope mutations including IlPRTLNAW, were seen for ISW9 by 45 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.

References

Norstrom2012 Melissa M. Norström, Marcus Buggert, Johanna Tauriainen, Wendy Hartogensis, Mattia C. Prosperi, Mark A. Wallet, Frederick M. Hecht, Marco Salemi, and Annika C. Karlsson. Combination of Immune and Viral Factors Distinguishes Low-Risk Versus High-Risk HIV-1 Disease Progression in HLA-B*5701 Subjects. J. Virol., 86(18):9802-9816, Sep 2012. PubMed ID: 22761389. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health